ATM and ovarian cancer: In fact, since the addition of ibrutinib to bendamustine plus rituximab can significantly improve outcomes of CLL patients [58] and PARP inhibitors have been proven to be highly effective in HR-impaired breast and ovarian cancer patients [59, 60], relapsed/refractory del(11q)/ATM-mutated CLL patients may potentially benefit from this combinatorial strategy.